CALGB 9511 was a phase II clinical trial led by the Cancer and Leukemia Group B (CALGB) that evaluated the use of pegylated asparaginase (PEG‑ASP) in adult patients with acute lymphoblastic leukemia (ALL), replacing native asparaginase used in the CALGB 8811 regimen
Contact Us
Thank you for visiting 3J Pharma Inc – Interactive Medical Corner. Please use the form below for general inquiries, collaborations, or website feedback.
Important: This form is not for patient-specific medical advice or emergency communication. Always consult your healthcare provider directly for clinical concerns.
SUBSCRIBE TO OUR NEWSLETTER
Error: Your Requested widget "Blog Subscriptions (Jetpack) " is not in the widget list.